COLLINSON
27.6.2024 10:01:32 CEST | Business Wire | Press release
Collinson, a global leader in travel experience and loyalty programmes, has announced a strategic partnership with World Nomads, the global travel insurance provider, including the launch of a new Annual Multi-Trip (AMT) product in the UK & Ireland.
The new product range will enhance the customer experience with the addition of increased coverage limits and new benefits that apply to both annual and single-trip policies, as well as innovative parametric service, SmartDelayTM. These enhancements ensure that travellers are better protected against a wider range of travel-related issues and unexpected flight delays or cancellations.
As part of the partnership, Collinson will be responsible for underwriting the AMT product as well as providing World Nomad customers with the use of its new parametric product SmartDelay.
SmartDelay is a real-time, parametric product which provides customers with a range of benefits in the event of a flight disruption, for example, providing access to over 1500 airport lounges or alternative benefits such as spa, sleep pods and restaurant discounts for travellers experiencing flight delays. SmartDelay also gives traveller access to Air Doctor, which connects travellers with private doctors and medical advice in destinations where public health services may be overstretched and/or unable to treat international travellers.
This new partnership supports Collinson’s UK and European growth ambitions, allowing the company to underwrite business for World Nomads in the UK, Ireland, Germany, Denmark, Belgium and Holland, with more to follow.
Greg Lawson, Head of Travel Insurance at Collinson, said: “Given both Collinson and World Nomads are established and respected brands by travellers globally, our collaboration in developing products that deliver above and beyond what today’s travellers demand from their travel insurance, demonstrates our commitment in offering fair value, flexibility and choice. The synergies of our companies make our partnership stronger, given Collinson’s experience as a renowned travel underwriter and World Nomad’s commitment to offer innovative travel insurance. It’s a great time to bring exciting products to the travel market to drive our shared UK and European growth ambitions.”
World Nomads’ AMT policy offers comprehensive and cost-effective coverage for frequent international and domestic travellers, allowing for multiple trips within a one-year period under a single policy. Additionally, a higher age limit (up to 69 years) and free coverage for children (aged under 18) when travelling with adult relatives or friends applies, making the AMT policy ideal for multigenerational travel.
Jonathan Frankham, General Manager, UK and Europe, World Nomad, said: “Both the introduction of the AMT product and the integration of Collinson as World Nomads’ new underwriters reflect our unwavering commitment to providing adventurous travellers with the most comprehensive and innovative coverage available. We are thrilled to offer an enhanced travel insurance experience that addresses the unique needs of today's travellers. With features like Air Doctor and SmartDelay, our travellers can tackle today's most common travel challenges with confidence, enjoying seamless access to medical care and luxurious airport lounges during delays.”
Issued by Rein4ce on behalf of Collinson
About Collinson
Collinson Insurance: specialty lines, travel and accident & health insurance, includes underwriting capacity, insurance products and access to expert TPAs in the UK and Europe. Our deep understanding of loyalty and membership programmes enables us to offer true differentiation, so clients have confidence in our partnership to deliver growth. SmartDelay is a parametric service that ensures airline passengers who have registered their flight are given access to an airport lounge or alternative benefit, in the event of a flight delay or cancellation. Priority Pass is the world’s original and market-leading airport experiences programme. We provide travellers with access to over 1,500 airport lounges and travel experiences in over 700 airports in 145 countries.
About World Nomads
World Nomads is a fast-growing, global travel insurance company. We provide inspirational stories, safety tips and specialised travel insurance for adventurous and independent travellers. Our online travel insurance offers cover to travellers from more than 100 countries and allows you to buy and claim online, 24/7, even while already traveling.
Our travel insurance focuses on what we believe is important to travellers: emergency medical and evacuation costs, baggage, trip cancellation, trip delay and trip interruption costs. We also offer cover for more than 200 adventure sports and activities, plus tech and gear. Our policies are underwritten by a suite of specialist travel insurers that provide 24/7 emergency assistance, customer service and claims support, making us a top choice for many of the world's leading adventure, independent and youth travel brands.
World Nomads is a part of the nib Group which provides health and medical insurance to more than 1.5 million Australian and New Zealand residents. We also provide health insurance to more than 170,000 international students and workers in Australia and are Australia’s third-largest travel insurer and global distributor of travel insurance through our business nib Travel.
https://www.worldnomads.com/uk/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627952877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom